Racemetyrosine
As of the edition of 20 October 2026, Racemetyrosine is a small molecule: stopped in 2023; acts on TH.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2023
- Kind
- Small molecule
- Registered trials
- 7, 3 stopped early
- Disease areas
- Cancer; Mental health; Skin and connective tissue; Digestive system; Hormones; Urinary and reproductive
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| TH | Tyrosine 3-monooxygenase | P07101 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 2 | 6 | 3 | 1 | 2 |
| Phase 3 | 1 | 0 | 0 | 1 |
| All trials | 7 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Tyme | Lead sponsor of trials | 2016 to now |
| Yamo Pharmaceuticals | Lead sponsor of trials | 2016 to now |
| Sarcoma Oncology Research Center | Lead sponsor of trials | 2020 to now |